WO2007110152A3 - Polylactid-nanopartikel - Google Patents

Polylactid-nanopartikel Download PDF

Info

Publication number
WO2007110152A3
WO2007110152A3 PCT/EP2007/002198 EP2007002198W WO2007110152A3 WO 2007110152 A3 WO2007110152 A3 WO 2007110152A3 EP 2007002198 W EP2007002198 W EP 2007002198W WO 2007110152 A3 WO2007110152 A3 WO 2007110152A3
Authority
WO
WIPO (PCT)
Prior art keywords
active substance
nanoparticles
targeted
delivery
poiy
Prior art date
Application number
PCT/EP2007/002198
Other languages
English (en)
French (fr)
Other versions
WO2007110152A8 (de
WO2007110152A2 (de
Inventor
Joerg Kreuter
Svetlana Gelperina
Olga Maksimenko
Alexander Khalanskiy
Original Assignee
Lohmann Therapie Syst Lts
Joerg Kreuter
Svetlana Gelperina
Olga Maksimenko
Alexander Khalanskiy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002644411A priority Critical patent/CA2644411A1/en
Priority to US12/225,555 priority patent/US8003128B2/en
Priority to NZ571354A priority patent/NZ571354A/en
Priority to AU2007229738A priority patent/AU2007229738A1/en
Priority to EP07711937A priority patent/EP1998752A2/de
Priority to BRPI0709352-7A priority patent/BRPI0709352A2/pt
Application filed by Lohmann Therapie Syst Lts, Joerg Kreuter, Svetlana Gelperina, Olga Maksimenko, Alexander Khalanskiy filed Critical Lohmann Therapie Syst Lts
Priority to MX2008011892A priority patent/MX2008011892A/es
Priority to JP2009500737A priority patent/JP2009530325A/ja
Publication of WO2007110152A2 publication Critical patent/WO2007110152A2/de
Publication of WO2007110152A8 publication Critical patent/WO2007110152A8/de
Publication of WO2007110152A3 publication Critical patent/WO2007110152A3/de
Priority to US13/136,015 priority patent/US20110293730A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Die vorliegende Erfindung betrifft ein System zur gezielten Wirkstoffzufuhr zur Verabreichung eines pharmakologisch wirksamen Wirkstoffes an das zentrale Nervensystem eines Säugers über die Blut-Hirn-Schranke, wobei das System zur gezielten Arzneistoff zufuhr Nanopartikel aus PoIy(DL-lactid) und/oder PoIy (DL-lactid-co-glycolid sowie wenigstens einen pharmakologisch wirksamen Wirkstoff, der in den Nanopartikeln absorbiert, an diese adsorbiert oder in diese eingearbeitet ist, umfasst, und entweder TPGS enthält oder einen Überzug aus dem oberflächenaktiven Stoff Pluronic 188, welcher auf den mit Wirkstoff beladenen Nanopartikeln abgeschieden ist, aufweist, sowie Verfahren zur Herstellung des Systems zur gezielten Wirkstoffzufuhr und die Verwendung des Systems zur gezielten Wirkstoffzufuhr zur Behandlung einer Krankheit oder einer Störung des zentralen Nervensystems.
PCT/EP2007/002198 2006-03-24 2007-03-13 Polylactid-nanopartikel WO2007110152A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US12/225,555 US8003128B2 (en) 2006-03-24 2007-03-13 Polylactide nanoparticles
NZ571354A NZ571354A (en) 2006-03-24 2007-03-13 Polylactide nanoparticles
AU2007229738A AU2007229738A1 (en) 2006-03-24 2007-03-13 Polylactide nanoparticles
EP07711937A EP1998752A2 (de) 2006-03-24 2007-03-13 Polylactid-nanopartikel
BRPI0709352-7A BRPI0709352A2 (pt) 2006-03-24 2007-03-13 método para preparar um sistema de direcionamanto de droga, sistema de direcionamento de droga, método para o tratamento de um doença ou de uma desordem do sistema nevorso central de um mamìfero e uso do sistema de direcionamento de droga
CA002644411A CA2644411A1 (en) 2006-03-24 2007-03-13 Polylactide nanoparticles
MX2008011892A MX2008011892A (es) 2006-03-24 2007-03-13 Nanoparticulas de polilactido.
JP2009500737A JP2009530325A (ja) 2006-03-24 2007-03-13 ポリラクチドナノ粒子
US13/136,015 US20110293730A1 (en) 2006-03-24 2011-07-20 Polylactide nanoparticles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006013531.8 2006-03-24
DE102006013531A DE102006013531A1 (de) 2006-03-24 2006-03-24 Polylactid-Nanopartikel

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/136,015 Division US20110293730A1 (en) 2006-03-24 2011-07-20 Polylactide nanoparticles

Publications (3)

Publication Number Publication Date
WO2007110152A2 WO2007110152A2 (de) 2007-10-04
WO2007110152A8 WO2007110152A8 (de) 2007-12-13
WO2007110152A3 true WO2007110152A3 (de) 2008-02-21

Family

ID=38110479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002198 WO2007110152A2 (de) 2006-03-24 2007-03-13 Polylactid-nanopartikel

Country Status (14)

Country Link
US (2) US8003128B2 (de)
EP (1) EP1998752A2 (de)
JP (1) JP2009530325A (de)
KR (1) KR20080111079A (de)
CN (1) CN101410099A (de)
AU (1) AU2007229738A1 (de)
BR (1) BRPI0709352A2 (de)
CA (1) CA2644411A1 (de)
DE (1) DE102006013531A1 (de)
IN (1) IN2008DE08036A (de)
MX (1) MX2008011892A (de)
NZ (1) NZ571354A (de)
RU (1) RU2423104C2 (de)
WO (1) WO2007110152A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
CN102088963A (zh) * 2008-05-06 2011-06-08 葛兰素集团有限公司 生物活性剂的囊封方法
WO2010005725A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EA014044B1 (ru) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты)
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (en) 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
EP2509634B1 (de) 2009-12-11 2019-03-06 Pfizer Inc Stabile formulierungen zur lyophilisation therapeutischer partikel
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US8974691B2 (en) 2010-09-24 2015-03-10 Fujimi Incorporated Composition for polishing and composition for rinsing
JP5687354B2 (ja) * 2010-11-26 2015-03-18 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｈｅ Ｗｉｔｗａｔｅｒｓｒａｎｄ， Ｊｏｈａｎｎｅｓｂｕｒｇ 薬物送達デバイス
WO2012135010A2 (en) * 2011-03-25 2012-10-04 Selecta Biosciences, Inc. Osmotic mediated release synthetic nanocarriers
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
GB201209517D0 (en) * 2012-05-29 2012-07-11 Univ Birmingham Nanoparticles
ES2656091T3 (es) * 2012-07-27 2018-02-23 Izumi Technology, Llc. Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan
RS58928B1 (sr) * 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
ES2732377T3 (es) 2012-09-17 2019-11-22 Pfizer Procedimiento de preparación de nanopartículas terapéuticas
CL2012003209A1 (es) * 2012-11-16 2013-04-19 Univ Santiago Chile Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
BR112016021130A2 (pt) 2014-03-14 2017-08-15 Pfizer Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas
CN103893769B (zh) * 2014-04-16 2016-03-23 江西科技师范大学 含聚乙丙交酯靶向高分子药物载体及其制备方法
CN109613177B (zh) * 2014-07-01 2021-08-20 科蒙森斯公司 用于鉴定羊水的诊断组合物
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
HRP20220304T1 (hr) 2015-06-24 2022-05-13 F. Hoffmann - La Roche Ag Anti-transferinska receptorska protutijela s prilagođenim afinitetom
RU2595859C1 (ru) * 2015-07-20 2016-08-27 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Полимеросодержащее лекарственное средство на основе противоопухолевого препарата этопозида
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
RU2606839C1 (ru) * 2015-10-26 2017-01-10 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Лекарственный препарат противотуберкулезного действия на основе D-циклосерина в виде лиофилизата и способ получения лекарственного препарата
RU2649743C1 (ru) * 2016-10-24 2018-04-04 Станислав Анатольевич Кедик Жидкая лекарственная форма, содержащая лекарственное вещество, помещенное в биоразлагаемые полимеры
CN106806352B (zh) * 2017-01-26 2019-01-15 中国人民解放军军事医学科学院毒物药物研究所 一种可缓释、靶向应用于神经退行性疾病的纳米药物
WO2018237004A1 (en) * 2017-06-20 2018-12-27 University Of Maryland, Baltimore RARY LIGAND CHARGED SELECTIVE NANOPARTICLES FOR HANDLING TARGET BONE GROWTH
RU2675810C1 (ru) * 2017-12-19 2018-12-25 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Полимерный комплекс для молекулярно-прицельной терапии и способ его получения
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
CN108395543B (zh) * 2018-05-31 2020-09-22 华南理工大学 一种改性聚轮烷、基于聚轮烷的载药胶束及其制备方法与应用
US20220175687A1 (en) * 2019-04-11 2022-06-09 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP3750524A1 (de) * 2019-06-13 2020-12-16 CAPNOMED GmbH Verzögerte und anhaltende abgabe von antikrebsmitteln
EP3750523A1 (de) * 2019-06-13 2020-12-16 CAPNOMED GmbH System zur abgabe eines wirkstoffes
RU2734710C1 (ru) * 2019-06-14 2020-10-22 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБТМ ФМБА России) Наночастицы на основе биодеградирующих полимеров с инкапсулированными в них противоопухолевыми препаратами
CN111939151A (zh) * 2020-07-04 2020-11-17 浙江工业大学 一种复合型阿霉素白蛋白纳米粒及其制备方法和应用
CN116018401A (zh) * 2020-07-29 2023-04-25 加利福尼亚大学董事会 驱动生肌性干细胞扩增的化学物混合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117454A (en) * 1994-02-28 2000-09-12 Medinova Medical Consulting Gmbh Drug targeting to the nervous system by nanoparticles
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2004084871A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
WO2004112695A2 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceutical Llc Methods and compositions for delivery of catecholic butanes for treatment of obesity
EP1795185A2 (de) * 2005-12-07 2007-06-13 Cordis Corporation Nano- und/oder Mikropartikelformulationen zur Behandlung von Gefäßerkrankungen auf der Basis lokaler Injektionen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
WO1998056361A1 (en) 1997-06-13 1998-12-17 Medinova Medical Consulting Gmbh Drug targeting system, method of its preparation and its use
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20060024248A1 (en) * 2003-03-23 2006-02-02 Combe Incorporated Composition and method employing membrane structured solid nanoparticles for enhanced delivery of oral care actives
WO2005003180A2 (en) * 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
US20050084456A1 (en) * 2003-10-21 2005-04-21 Liping Tang Functionalized particles
KR101123520B1 (ko) * 2003-12-04 2012-03-13 디에스엠 아이피 어셋츠 비.브이. 자외선 필터 활성을 갖는 미세캡슐 및 그의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117454A (en) * 1994-02-28 2000-09-12 Medinova Medical Consulting Gmbh Drug targeting to the nervous system by nanoparticles
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2004084871A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
WO2004112695A2 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceutical Llc Methods and compositions for delivery of catecholic butanes for treatment of obesity
EP1795185A2 (de) * 2005-12-07 2007-06-13 Cordis Corporation Nano- und/oder Mikropartikelformulationen zur Behandlung von Gefäßerkrankungen auf der Basis lokaler Injektionen

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DINTAMAN JAY M ET AL: "Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS)", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 16, no. 10, October 1999 (1999-10-01), pages 1550 - 1556, XP002437572, ISSN: 0724-8741 *
FENG S-S ET AL: "Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases", CHEMICAL ENGINEERING SCIENCE, OXFORD, GB, vol. 58, no. 18, September 2003 (2003-09-01), pages 4087 - 4114, XP004453411, ISSN: 0009-2509 *
MU ET AL: "Application of TPGS in polymeric nanoparticulate drug delivery system", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM,, NL, vol. 47, no. 1, 15 January 2006 (2006-01-15), pages 90 - 97, XP005251979, ISSN: 0927-7765 *
MU L ET AL: "Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol<(>R))", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 80, no. 1-3, 23 April 2002 (2002-04-23), pages 129 - 144, XP004348630, ISSN: 0168-3659 *
MUELLER R H ET AL: "Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 89, no. 1, 1993, pages 25 - 31, XP002456391, ISSN: 0378-5173 *
REDHEAD H M ET AL: "Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation", JOURNAL OF CONTROLLED RELEASE, vol. 70, no. 3, 23 February 2001 (2001-02-23), pages 353 - 363, XP002456390, ISSN: 0168-3659 *
RUAN G ET AL: "Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 84, no. 3, 5 December 2002 (2002-12-05), pages 151 - 160, XP004395986, ISSN: 0168-3659 *
YOON JEONG PARK ET AL: "SURFACE-MODIFIED POLY(LACTIDE-CO-GLYCOLIDE) NANOSPHERES FOR TARGETED BONE IMAGING WITH ENHANCED LABELING AND DELIVERY OF RADIOISOTOPE", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, WILEY, NEW YORK, NY, US, vol. 67A, no. 3, 2003, pages 751 - 760, XP008039693, ISSN: 0021-9304 *
ZHANG ET AL: "Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 27, no. 2, January 2006 (2006-01-01), pages 262 - 270, XP005071172, ISSN: 0142-9612 *

Also Published As

Publication number Publication date
EP1998752A2 (de) 2008-12-10
US20110293730A1 (en) 2011-12-01
WO2007110152A8 (de) 2007-12-13
US8003128B2 (en) 2011-08-23
IN2008DE08036A (de) 2009-03-20
RU2423104C2 (ru) 2011-07-10
DE102006013531A1 (de) 2007-09-27
US20090263491A1 (en) 2009-10-22
AU2007229738A1 (en) 2007-10-04
KR20080111079A (ko) 2008-12-22
MX2008011892A (es) 2008-11-14
BRPI0709352A2 (pt) 2011-07-12
CA2644411A1 (en) 2007-10-04
CN101410099A (zh) 2009-04-15
RU2008140367A (ru) 2010-04-20
JP2009530325A (ja) 2009-08-27
NZ571354A (en) 2011-02-25
WO2007110152A2 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2007110152A3 (de) Polylactid-nanopartikel
Zhang et al. Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management
JP6657454B2 (ja) ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
JP5411504B2 (ja) 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用
Sharma et al. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis
Mercadante The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing
Warren et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group
Wermeling Intranasal delivery of antiepileptic medications for treatment of seizures
Onoshita et al. The behavior of PLGA microspheres containing rifampicin in alveolar macrophages
Dube et al. Tuberculosis: from molecular pathogenesis to effective drug carrier design
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
WO2007117661A3 (en) Drug microparticles
CA2534997A1 (en) Methods for administering aripiprazole
WO2009104175A3 (en) Use of electrospun microtubes for drug delivery
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
MX350871B (es) Vehiculo masticable para absorcion bucal.
Paul et al. Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles
WO2007106550A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2009127922A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2004098564A3 (en) Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2007124224A3 (en) Method for delivering particulate drugs to tissues
Kassick et al. Covalently loaded naloxone nanoparticles as a long-acting medical countermeasure to opioid poisoning
Tang et al. Enhanced efficacy of local etoposide delivery by poly (ether-anhydride) particles against small cell lung cancer in vivo
WO2008051527A3 (en) Sustained release of agents for localized pain management

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07711937

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007711937

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2644411

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 571354

Country of ref document: NZ

Ref document number: MX/a/2008/011892

Country of ref document: MX

Ref document number: 194209

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12008502113

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2009500737

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007229738

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12225555

Country of ref document: US

Ref document number: 200780010641.3

Country of ref document: CN

Ref document number: 8036/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008140367

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007229738

Country of ref document: AU

Date of ref document: 20070313

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087025603

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0709352

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080922